Saturday, November 14, 2026
ExploreSearch
finance.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus

View original at finance.yahoo.com
Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus Last Friday, the three most widely followed benchmark indexes closed a losing week…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Since 2012, the Top 10 portfolio has produced a cumulative return of +2,530.8% through the end of November 2025 vs. +562% for the S&P 500 index and +401% for the equal-weight version of the index

    80% confidence

  • For the full year 2024, the ECDP portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL

    80% confidence

  • The Top 10 portfolio returned +25.4% in 2025 (through the end of November) vs. +17.8% for the S&P 500 index and +10.9% for the equal-weight version of the index

    80% confidence

  • Hypothetical portfolio of Zacks Rank #1 stocks returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index

    80% confidence

  • The ECDP portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL

    80% confidence

  • The ECAP portfolio returned -4.7% in 2022 vs. the S&P 500 index's -17.96%

    80% confidence

  • Year-to-date through September 30th, the ECAP portfolio returned +2.72% vs. +14.84% gain for the S&P 500 index

    80% confidence

  • For the year 2024, the ECAP portfolio returned +16.26% vs. +24.89% for the S&P 500 index

    80% confidence

  • Hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index

    80% confidence

  • The ECDP portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL

    80% confidence

  • The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index

    80% confidence

  • In 2022, the Zacks Focus List portfolio returned -15.2% vs. the S&P 500 index's -17.96%

    80% confidence

  • The Top 10 portfolio returned +25.15% in 2023 vs. +26.28% for the S&P 500 index

    80% confidence

  • The Zacks Earnings Certain Admiral Portfolio (ECAP) returned -1.30% in the third quarter of 2025 vs. the S&P 500 index's +8.1% gain

    80% confidence

  • In 2023, the ECAP portfolio returned +12.17% vs. +26.28% for the S&P 500 index

    80% confidence

  • The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -0.01% in 2025 Q3 vs. the S&P 500 index's +8.1% gain and the Dividend Aristocrats ETF's (NOBL) +2.90% return

    80% confidence

  • The 50-stock Focus List portfolio returned +22% in 2025 (through November 30th, 2025) vs. +17.8% for the S&P 500 index and +10.9% for the equal-weight version of the index

    80% confidence

  • The Top 10 portfolio has produced an average return of +26.1% in the period 2012 through November 30, 2025, vs. +13.2% for the S&P 500 index and +10.5% for the equal-weight version of the index

    80% confidence

  • Year-to-date (through September 30th), the ECDP portfolio returned +1.58% vs. +5.15% gain for the Dividend Aristocrat ETF

    80% confidence

  • The Zacks Model Portfolio consisting of Zacks Rank #1 stocks has outperformed the S&P index by more than 12 percentage points since 1988, generating an annualized average return of +23.9% vs. +11.5% for the S&P 500 index through December 1st, 2025

    80% confidence

  • The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index

    80% confidence

  • The Zacks Focus List portfolio returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index

    80% confidence

  • A hypothetical portfolio of Zacks Rank #1 (Strong Buy) stocks returned +14.3% in 2025 (through December 1st) vs. +14.9% for the S&P 500 index

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com
Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus — Source | Via News | finance.via.news